nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—NR1I2—bone cancer	0.776	0.835	CbGaD
Rifaximin—CYP3A4—bone cancer	0.154	0.165	CbGaD
Rifaximin—Rifampicin—NR1I2—bone cancer	0.00255	0.517	CrCbGaD
Rifaximin—Rifabutin—CYP3A4—bone cancer	0.00107	0.216	CrCbGaD
Rifaximin—Rifapentine—CYP3A4—bone cancer	0.000809	0.164	CrCbGaD
Rifaximin—Rifampicin—CYP3A4—bone cancer	0.000505	0.102	CrCbGaD
Rifaximin—Menopausal symptoms—Doxorubicin—bone cancer	0.00022	0.00337	CcSEcCtD
Rifaximin—Anaphylactic shock—Cisplatin—bone cancer	0.000214	0.00329	CcSEcCtD
Rifaximin—Infection—Cisplatin—bone cancer	0.000213	0.00326	CcSEcCtD
Rifaximin—Hypoglycaemia—Doxorubicin—bone cancer	0.000212	0.00326	CcSEcCtD
Rifaximin—Nervous system disorder—Cisplatin—bone cancer	0.00021	0.00322	CcSEcCtD
Rifaximin—Dehydration—Epirubicin—bone cancer	0.000208	0.00319	CcSEcCtD
Rifaximin—Skin disorder—Cisplatin—bone cancer	0.000208	0.00319	CcSEcCtD
Rifaximin—Hyponatraemia—Doxorubicin—bone cancer	0.000208	0.00319	CcSEcCtD
Rifaximin—Pain in extremity—Doxorubicin—bone cancer	0.000207	0.00318	CcSEcCtD
Rifaximin—Hyperhidrosis—Cisplatin—bone cancer	0.000207	0.00318	CcSEcCtD
Rifaximin—Abdominal pain upper—Epirubicin—bone cancer	0.000205	0.00314	CcSEcCtD
Rifaximin—Anorexia—Cisplatin—bone cancer	0.000204	0.00313	CcSEcCtD
Rifaximin—Migraine—Doxorubicin—bone cancer	0.000204	0.00313	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000202	0.00309	CcSEcCtD
Rifaximin—Hypotension—Cisplatin—bone cancer	0.0002	0.00307	CcSEcCtD
Rifaximin—Nasopharyngitis—Epirubicin—bone cancer	0.0002	0.00307	CcSEcCtD
Rifaximin—Abdominal discomfort—Methotrexate—bone cancer	0.000198	0.00304	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000195	0.00299	CcSEcCtD
Rifaximin—Abdominal distension—Epirubicin—bone cancer	0.000195	0.00299	CcSEcCtD
Rifaximin—Dysphagia—Epirubicin—bone cancer	0.000194	0.00297	CcSEcCtD
Rifaximin—Dysuria—Methotrexate—bone cancer	0.000193	0.00297	CcSEcCtD
Rifaximin—Neutropenia—Methotrexate—bone cancer	0.000193	0.00297	CcSEcCtD
Rifaximin—Dehydration—Doxorubicin—bone cancer	0.000193	0.00295	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Methotrexate—bone cancer	0.000192	0.00295	CcSEcCtD
Rifaximin—Dyspnoea—Cisplatin—bone cancer	0.000191	0.00293	CcSEcCtD
Rifaximin—Abdominal pain upper—Doxorubicin—bone cancer	0.000189	0.0029	CcSEcCtD
Rifaximin—Photosensitivity reaction—Methotrexate—bone cancer	0.000189	0.00289	CcSEcCtD
Rifaximin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000187	0.00286	CcSEcCtD
Rifaximin—Decreased appetite—Cisplatin—bone cancer	0.000186	0.00286	CcSEcCtD
Rifaximin—Pneumonia—Methotrexate—bone cancer	0.000186	0.00284	CcSEcCtD
Rifaximin—Nasopharyngitis—Doxorubicin—bone cancer	0.000185	0.00284	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000185	0.00284	CcSEcCtD
Rifaximin—Infestation NOS—Methotrexate—bone cancer	0.000184	0.00283	CcSEcCtD
Rifaximin—Infestation—Methotrexate—bone cancer	0.000184	0.00283	CcSEcCtD
Rifaximin—Depression—Methotrexate—bone cancer	0.000184	0.00282	CcSEcCtD
Rifaximin—Pain—Cisplatin—bone cancer	0.000183	0.00281	CcSEcCtD
Rifaximin—Dysuria—Epirubicin—bone cancer	0.000181	0.00278	CcSEcCtD
Rifaximin—Neutropenia—Epirubicin—bone cancer	0.000181	0.00278	CcSEcCtD
Rifaximin—Abdominal distension—Doxorubicin—bone cancer	0.00018	0.00276	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Epirubicin—bone cancer	0.00018	0.00276	CcSEcCtD
Rifaximin—Dysphagia—Doxorubicin—bone cancer	0.000179	0.00275	CcSEcCtD
Rifaximin—Pollakiuria—Epirubicin—bone cancer	0.000179	0.00274	CcSEcCtD
Rifaximin—Photosensitivity reaction—Epirubicin—bone cancer	0.000177	0.00271	CcSEcCtD
Rifaximin—Feeling abnormal—Cisplatin—bone cancer	0.000177	0.00271	CcSEcCtD
Rifaximin—Weight increased—Epirubicin—bone cancer	0.000176	0.0027	CcSEcCtD
Rifaximin—Haematuria—Methotrexate—bone cancer	0.000176	0.0027	CcSEcCtD
Rifaximin—Weight decreased—Epirubicin—bone cancer	0.000175	0.00268	CcSEcCtD
Rifaximin—Hyperglycaemia—Epirubicin—bone cancer	0.000175	0.00268	CcSEcCtD
Rifaximin—Epistaxis—Methotrexate—bone cancer	0.000174	0.00267	CcSEcCtD
Rifaximin—Pneumonia—Epirubicin—bone cancer	0.000174	0.00266	CcSEcCtD
Rifaximin—Infestation NOS—Epirubicin—bone cancer	0.000173	0.00265	CcSEcCtD
Rifaximin—Infestation—Epirubicin—bone cancer	0.000173	0.00265	CcSEcCtD
Rifaximin—Body temperature increased—Cisplatin—bone cancer	0.000169	0.0026	CcSEcCtD
Rifaximin—Dysuria—Doxorubicin—bone cancer	0.000167	0.00257	CcSEcCtD
Rifaximin—Neutropenia—Doxorubicin—bone cancer	0.000167	0.00257	CcSEcCtD
Rifaximin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000166	0.00255	CcSEcCtD
Rifaximin—Haemoglobin—Methotrexate—bone cancer	0.000166	0.00255	CcSEcCtD
Rifaximin—Haemorrhage—Methotrexate—bone cancer	0.000166	0.00254	CcSEcCtD
Rifaximin—Pollakiuria—Doxorubicin—bone cancer	0.000165	0.00254	CcSEcCtD
Rifaximin—Haematuria—Epirubicin—bone cancer	0.000165	0.00252	CcSEcCtD
Rifaximin—Pharyngitis—Methotrexate—bone cancer	0.000164	0.00252	CcSEcCtD
Rifaximin—Urinary tract disorder—Methotrexate—bone cancer	0.000164	0.00251	CcSEcCtD
Rifaximin—Photosensitivity reaction—Doxorubicin—bone cancer	0.000163	0.00251	CcSEcCtD
Rifaximin—Weight increased—Doxorubicin—bone cancer	0.000163	0.0025	CcSEcCtD
Rifaximin—Epistaxis—Epirubicin—bone cancer	0.000163	0.0025	CcSEcCtD
Rifaximin—Urethral disorder—Methotrexate—bone cancer	0.000162	0.00249	CcSEcCtD
Rifaximin—Weight decreased—Doxorubicin—bone cancer	0.000162	0.00248	CcSEcCtD
Rifaximin—Hyperglycaemia—Doxorubicin—bone cancer	0.000162	0.00248	CcSEcCtD
Rifaximin—Pneumonia—Doxorubicin—bone cancer	0.000161	0.00246	CcSEcCtD
Rifaximin—Infestation NOS—Doxorubicin—bone cancer	0.00016	0.00245	CcSEcCtD
Rifaximin—Infestation—Doxorubicin—bone cancer	0.00016	0.00245	CcSEcCtD
Rifaximin—Hypersensitivity—Cisplatin—bone cancer	0.000158	0.00242	CcSEcCtD
Rifaximin—Haemoglobin—Epirubicin—bone cancer	0.000156	0.00239	CcSEcCtD
Rifaximin—Rhinitis—Epirubicin—bone cancer	0.000155	0.00238	CcSEcCtD
Rifaximin—Haemorrhage—Epirubicin—bone cancer	0.000155	0.00238	CcSEcCtD
Rifaximin—Tinnitus—Methotrexate—bone cancer	0.000154	0.00237	CcSEcCtD
Rifaximin—Hypoaesthesia—Epirubicin—bone cancer	0.000154	0.00236	CcSEcCtD
Rifaximin—Asthenia—Cisplatin—bone cancer	0.000154	0.00236	CcSEcCtD
Rifaximin—Pharyngitis—Epirubicin—bone cancer	0.000154	0.00236	CcSEcCtD
Rifaximin—Urinary tract disorder—Epirubicin—bone cancer	0.000153	0.00235	CcSEcCtD
Rifaximin—Oedema peripheral—Epirubicin—bone cancer	0.000153	0.00234	CcSEcCtD
Rifaximin—Haematuria—Doxorubicin—bone cancer	0.000152	0.00233	CcSEcCtD
Rifaximin—Urethral disorder—Epirubicin—bone cancer	0.000152	0.00233	CcSEcCtD
Rifaximin—Epistaxis—Doxorubicin—bone cancer	0.000151	0.00231	CcSEcCtD
Rifaximin—Angiopathy—Methotrexate—bone cancer	0.00015	0.0023	CcSEcCtD
Rifaximin—Mediastinal disorder—Methotrexate—bone cancer	0.000149	0.00229	CcSEcCtD
Rifaximin—Diarrhoea—Cisplatin—bone cancer	0.000147	0.00225	CcSEcCtD
Rifaximin—Mental disorder—Methotrexate—bone cancer	0.000145	0.00222	CcSEcCtD
Rifaximin—Tinnitus—Epirubicin—bone cancer	0.000144	0.00221	CcSEcCtD
Rifaximin—Malnutrition—Methotrexate—bone cancer	0.000144	0.00221	CcSEcCtD
Rifaximin—Haemoglobin—Doxorubicin—bone cancer	0.000144	0.00221	CcSEcCtD
Rifaximin—Flushing—Epirubicin—bone cancer	0.000144	0.0022	CcSEcCtD
Rifaximin—Rhinitis—Doxorubicin—bone cancer	0.000144	0.0022	CcSEcCtD
Rifaximin—Haemorrhage—Doxorubicin—bone cancer	0.000143	0.0022	CcSEcCtD
Rifaximin—Hypoaesthesia—Doxorubicin—bone cancer	0.000143	0.00219	CcSEcCtD
Rifaximin—Pharyngitis—Doxorubicin—bone cancer	0.000142	0.00218	CcSEcCtD
Rifaximin—Urinary tract disorder—Doxorubicin—bone cancer	0.000142	0.00217	CcSEcCtD
Rifaximin—Oedema peripheral—Doxorubicin—bone cancer	0.000141	0.00217	CcSEcCtD
Rifaximin—Angiopathy—Epirubicin—bone cancer	0.000141	0.00216	CcSEcCtD
Rifaximin—Urethral disorder—Doxorubicin—bone cancer	0.000141	0.00215	CcSEcCtD
Rifaximin—Mediastinal disorder—Epirubicin—bone cancer	0.00014	0.00214	CcSEcCtD
Rifaximin—Back pain—Methotrexate—bone cancer	0.000139	0.00214	CcSEcCtD
Rifaximin—Vomiting—Cisplatin—bone cancer	0.000136	0.00209	CcSEcCtD
Rifaximin—Mental disorder—Epirubicin—bone cancer	0.000136	0.00208	CcSEcCtD
Rifaximin—Rash—Cisplatin—bone cancer	0.000135	0.00207	CcSEcCtD
Rifaximin—Dermatitis—Cisplatin—bone cancer	0.000135	0.00207	CcSEcCtD
Rifaximin—Malnutrition—Epirubicin—bone cancer	0.000135	0.00207	CcSEcCtD
Rifaximin—Ill-defined disorder—Methotrexate—bone cancer	0.000134	0.00205	CcSEcCtD
Rifaximin—Tinnitus—Doxorubicin—bone cancer	0.000134	0.00205	CcSEcCtD
Rifaximin—Anaemia—Methotrexate—bone cancer	0.000133	0.00204	CcSEcCtD
Rifaximin—Flushing—Doxorubicin—bone cancer	0.000133	0.00204	CcSEcCtD
Rifaximin—Flatulence—Epirubicin—bone cancer	0.000133	0.00204	CcSEcCtD
Rifaximin—Back pain—Epirubicin—bone cancer	0.00013	0.002	CcSEcCtD
Rifaximin—Angiopathy—Doxorubicin—bone cancer	0.00013	0.00199	CcSEcCtD
Rifaximin—Malaise—Methotrexate—bone cancer	0.00013	0.00199	CcSEcCtD
Rifaximin—Muscle spasms—Epirubicin—bone cancer	0.00013	0.00199	CcSEcCtD
Rifaximin—Vertigo—Methotrexate—bone cancer	0.000129	0.00199	CcSEcCtD
Rifaximin—Mediastinal disorder—Doxorubicin—bone cancer	0.000129	0.00198	CcSEcCtD
Rifaximin—Nausea—Cisplatin—bone cancer	0.000127	0.00195	CcSEcCtD
Rifaximin—Cough—Methotrexate—bone cancer	0.000126	0.00193	CcSEcCtD
Rifaximin—Mental disorder—Doxorubicin—bone cancer	0.000126	0.00193	CcSEcCtD
Rifaximin—Ill-defined disorder—Epirubicin—bone cancer	0.000125	0.00192	CcSEcCtD
Rifaximin—Malnutrition—Doxorubicin—bone cancer	0.000125	0.00191	CcSEcCtD
Rifaximin—Anaemia—Epirubicin—bone cancer	0.000125	0.00191	CcSEcCtD
Rifaximin—Flatulence—Doxorubicin—bone cancer	0.000123	0.00189	CcSEcCtD
Rifaximin—Arthralgia—Methotrexate—bone cancer	0.000123	0.00188	CcSEcCtD
Rifaximin—Myalgia—Methotrexate—bone cancer	0.000123	0.00188	CcSEcCtD
Rifaximin—Chest pain—Methotrexate—bone cancer	0.000123	0.00188	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000122	0.00187	CcSEcCtD
Rifaximin—Malaise—Epirubicin—bone cancer	0.000122	0.00186	CcSEcCtD
Rifaximin—Discomfort—Methotrexate—bone cancer	0.000121	0.00186	CcSEcCtD
Rifaximin—Vertigo—Epirubicin—bone cancer	0.000121	0.00186	CcSEcCtD
Rifaximin—Syncope—Epirubicin—bone cancer	0.000121	0.00185	CcSEcCtD
Rifaximin—Back pain—Doxorubicin—bone cancer	0.000121	0.00185	CcSEcCtD
Rifaximin—Muscle spasms—Doxorubicin—bone cancer	0.00012	0.00184	CcSEcCtD
Rifaximin—Confusional state—Methotrexate—bone cancer	0.000119	0.00182	CcSEcCtD
Rifaximin—Loss of consciousness—Epirubicin—bone cancer	0.000119	0.00182	CcSEcCtD
Rifaximin—Cough—Epirubicin—bone cancer	0.000118	0.0018	CcSEcCtD
Rifaximin—Anaphylactic shock—Methotrexate—bone cancer	0.000118	0.0018	CcSEcCtD
Rifaximin—Infection—Methotrexate—bone cancer	0.000117	0.00179	CcSEcCtD
Rifaximin—Ill-defined disorder—Doxorubicin—bone cancer	0.000116	0.00178	CcSEcCtD
Rifaximin—Nervous system disorder—Methotrexate—bone cancer	0.000115	0.00177	CcSEcCtD
Rifaximin—Anaemia—Doxorubicin—bone cancer	0.000115	0.00177	CcSEcCtD
Rifaximin—Chest pain—Epirubicin—bone cancer	0.000115	0.00176	CcSEcCtD
Rifaximin—Myalgia—Epirubicin—bone cancer	0.000115	0.00176	CcSEcCtD
Rifaximin—Arthralgia—Epirubicin—bone cancer	0.000115	0.00176	CcSEcCtD
Rifaximin—Skin disorder—Methotrexate—bone cancer	0.000114	0.00175	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000114	0.00175	CcSEcCtD
Rifaximin—Hyperhidrosis—Methotrexate—bone cancer	0.000114	0.00174	CcSEcCtD
Rifaximin—Discomfort—Epirubicin—bone cancer	0.000113	0.00174	CcSEcCtD
Rifaximin—Malaise—Doxorubicin—bone cancer	0.000113	0.00173	CcSEcCtD
Rifaximin—Dry mouth—Epirubicin—bone cancer	0.000112	0.00172	CcSEcCtD
Rifaximin—Vertigo—Doxorubicin—bone cancer	0.000112	0.00172	CcSEcCtD
Rifaximin—Anorexia—Methotrexate—bone cancer	0.000112	0.00172	CcSEcCtD
Rifaximin—Syncope—Doxorubicin—bone cancer	0.000112	0.00172	CcSEcCtD
Rifaximin—Confusional state—Epirubicin—bone cancer	0.000111	0.0017	CcSEcCtD
Rifaximin—Anaphylactic shock—Epirubicin—bone cancer	0.00011	0.00169	CcSEcCtD
Rifaximin—Hypotension—Methotrexate—bone cancer	0.00011	0.00169	CcSEcCtD
Rifaximin—Loss of consciousness—Doxorubicin—bone cancer	0.00011	0.00168	CcSEcCtD
Rifaximin—Infection—Epirubicin—bone cancer	0.000109	0.00168	CcSEcCtD
Rifaximin—Cough—Doxorubicin—bone cancer	0.000109	0.00167	CcSEcCtD
Rifaximin—Shock—Epirubicin—bone cancer	0.000108	0.00166	CcSEcCtD
Rifaximin—Nervous system disorder—Epirubicin—bone cancer	0.000108	0.00166	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000107	0.00164	CcSEcCtD
Rifaximin—Skin disorder—Epirubicin—bone cancer	0.000107	0.00164	CcSEcCtD
Rifaximin—Hyperhidrosis—Epirubicin—bone cancer	0.000106	0.00163	CcSEcCtD
Rifaximin—Insomnia—Methotrexate—bone cancer	0.000106	0.00163	CcSEcCtD
Rifaximin—Myalgia—Doxorubicin—bone cancer	0.000106	0.00163	CcSEcCtD
Rifaximin—Arthralgia—Doxorubicin—bone cancer	0.000106	0.00163	CcSEcCtD
Rifaximin—Chest pain—Doxorubicin—bone cancer	0.000106	0.00163	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000106	0.00162	CcSEcCtD
Rifaximin—Discomfort—Doxorubicin—bone cancer	0.000105	0.00161	CcSEcCtD
Rifaximin—Anorexia—Epirubicin—bone cancer	0.000105	0.00161	CcSEcCtD
Rifaximin—Dyspnoea—Methotrexate—bone cancer	0.000105	0.00161	CcSEcCtD
Rifaximin—Dry mouth—Doxorubicin—bone cancer	0.000104	0.00159	CcSEcCtD
Rifaximin—Hypotension—Epirubicin—bone cancer	0.000103	0.00158	CcSEcCtD
Rifaximin—Confusional state—Doxorubicin—bone cancer	0.000103	0.00157	CcSEcCtD
Rifaximin—Decreased appetite—Methotrexate—bone cancer	0.000102	0.00157	CcSEcCtD
Rifaximin—Anaphylactic shock—Doxorubicin—bone cancer	0.000102	0.00156	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000102	0.00156	CcSEcCtD
Rifaximin—Fatigue—Methotrexate—bone cancer	0.000101	0.00155	CcSEcCtD
Rifaximin—Infection—Doxorubicin—bone cancer	0.000101	0.00155	CcSEcCtD
Rifaximin—Pain—Methotrexate—bone cancer	0.000101	0.00154	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.0001	0.00154	CcSEcCtD
Rifaximin—Shock—Doxorubicin—bone cancer	0.0001	0.00154	CcSEcCtD
Rifaximin—Nervous system disorder—Doxorubicin—bone cancer	9.99e-05	0.00153	CcSEcCtD
Rifaximin—Insomnia—Epirubicin—bone cancer	9.96e-05	0.00153	CcSEcCtD
Rifaximin—Skin disorder—Doxorubicin—bone cancer	9.89e-05	0.00152	CcSEcCtD
Rifaximin—Hyperhidrosis—Doxorubicin—bone cancer	9.85e-05	0.00151	CcSEcCtD
Rifaximin—Dyspnoea—Epirubicin—bone cancer	9.81e-05	0.0015	CcSEcCtD
Rifaximin—Anorexia—Doxorubicin—bone cancer	9.71e-05	0.00149	CcSEcCtD
Rifaximin—Feeling abnormal—Methotrexate—bone cancer	9.69e-05	0.00149	CcSEcCtD
Rifaximin—Gastrointestinal pain—Methotrexate—bone cancer	9.62e-05	0.00147	CcSEcCtD
Rifaximin—Decreased appetite—Epirubicin—bone cancer	9.57e-05	0.00147	CcSEcCtD
Rifaximin—Hypotension—Doxorubicin—bone cancer	9.52e-05	0.00146	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Epirubicin—bone cancer	9.5e-05	0.00146	CcSEcCtD
Rifaximin—Fatigue—Epirubicin—bone cancer	9.49e-05	0.00146	CcSEcCtD
Rifaximin—Constipation—Epirubicin—bone cancer	9.41e-05	0.00144	CcSEcCtD
Rifaximin—Pain—Epirubicin—bone cancer	9.41e-05	0.00144	CcSEcCtD
Rifaximin—Urticaria—Methotrexate—bone cancer	9.34e-05	0.00143	CcSEcCtD
Rifaximin—Abdominal pain—Methotrexate—bone cancer	9.3e-05	0.00143	CcSEcCtD
Rifaximin—Body temperature increased—Methotrexate—bone cancer	9.3e-05	0.00143	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Doxorubicin—bone cancer	9.28e-05	0.00142	CcSEcCtD
Rifaximin—Insomnia—Doxorubicin—bone cancer	9.21e-05	0.00141	CcSEcCtD
Rifaximin—Dyspnoea—Doxorubicin—bone cancer	9.08e-05	0.00139	CcSEcCtD
Rifaximin—Feeling abnormal—Epirubicin—bone cancer	9.07e-05	0.00139	CcSEcCtD
Rifaximin—Gastrointestinal pain—Epirubicin—bone cancer	9e-05	0.00138	CcSEcCtD
Rifaximin—Decreased appetite—Doxorubicin—bone cancer	8.85e-05	0.00136	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Doxorubicin—bone cancer	8.79e-05	0.00135	CcSEcCtD
Rifaximin—Fatigue—Doxorubicin—bone cancer	8.78e-05	0.00135	CcSEcCtD
Rifaximin—Urticaria—Epirubicin—bone cancer	8.75e-05	0.00134	CcSEcCtD
Rifaximin—Pain—Doxorubicin—bone cancer	8.71e-05	0.00134	CcSEcCtD
Rifaximin—Constipation—Doxorubicin—bone cancer	8.71e-05	0.00134	CcSEcCtD
Rifaximin—Body temperature increased—Epirubicin—bone cancer	8.7e-05	0.00133	CcSEcCtD
Rifaximin—Abdominal pain—Epirubicin—bone cancer	8.7e-05	0.00133	CcSEcCtD
Rifaximin—Hypersensitivity—Methotrexate—bone cancer	8.67e-05	0.00133	CcSEcCtD
Rifaximin—Asthenia—Methotrexate—bone cancer	8.44e-05	0.00129	CcSEcCtD
Rifaximin—Feeling abnormal—Doxorubicin—bone cancer	8.39e-05	0.00129	CcSEcCtD
Rifaximin—Gastrointestinal pain—Doxorubicin—bone cancer	8.33e-05	0.00128	CcSEcCtD
Rifaximin—Pruritus—Methotrexate—bone cancer	8.32e-05	0.00128	CcSEcCtD
Rifaximin—Hypersensitivity—Epirubicin—bone cancer	8.11e-05	0.00124	CcSEcCtD
Rifaximin—Urticaria—Doxorubicin—bone cancer	8.09e-05	0.00124	CcSEcCtD
Rifaximin—Abdominal pain—Doxorubicin—bone cancer	8.05e-05	0.00123	CcSEcCtD
Rifaximin—Body temperature increased—Doxorubicin—bone cancer	8.05e-05	0.00123	CcSEcCtD
Rifaximin—Diarrhoea—Methotrexate—bone cancer	8.05e-05	0.00123	CcSEcCtD
Rifaximin—Asthenia—Epirubicin—bone cancer	7.9e-05	0.00121	CcSEcCtD
Rifaximin—Pruritus—Epirubicin—bone cancer	7.79e-05	0.00119	CcSEcCtD
Rifaximin—Dizziness—Methotrexate—bone cancer	7.78e-05	0.00119	CcSEcCtD
Rifaximin—Diarrhoea—Epirubicin—bone cancer	7.53e-05	0.00115	CcSEcCtD
Rifaximin—Hypersensitivity—Doxorubicin—bone cancer	7.5e-05	0.00115	CcSEcCtD
Rifaximin—Vomiting—Methotrexate—bone cancer	7.48e-05	0.00115	CcSEcCtD
Rifaximin—Rash—Methotrexate—bone cancer	7.42e-05	0.00114	CcSEcCtD
Rifaximin—Dermatitis—Methotrexate—bone cancer	7.41e-05	0.00114	CcSEcCtD
Rifaximin—Headache—Methotrexate—bone cancer	7.37e-05	0.00113	CcSEcCtD
Rifaximin—Asthenia—Doxorubicin—bone cancer	7.31e-05	0.00112	CcSEcCtD
Rifaximin—Dizziness—Epirubicin—bone cancer	7.28e-05	0.00112	CcSEcCtD
Rifaximin—Pruritus—Doxorubicin—bone cancer	7.21e-05	0.0011	CcSEcCtD
Rifaximin—Vomiting—Epirubicin—bone cancer	7e-05	0.00107	CcSEcCtD
Rifaximin—Nausea—Methotrexate—bone cancer	6.99e-05	0.00107	CcSEcCtD
Rifaximin—Diarrhoea—Doxorubicin—bone cancer	6.97e-05	0.00107	CcSEcCtD
Rifaximin—Rash—Epirubicin—bone cancer	6.94e-05	0.00106	CcSEcCtD
Rifaximin—Dermatitis—Epirubicin—bone cancer	6.93e-05	0.00106	CcSEcCtD
Rifaximin—Headache—Epirubicin—bone cancer	6.9e-05	0.00106	CcSEcCtD
Rifaximin—Dizziness—Doxorubicin—bone cancer	6.74e-05	0.00103	CcSEcCtD
Rifaximin—Nausea—Epirubicin—bone cancer	6.54e-05	0.001	CcSEcCtD
Rifaximin—Vomiting—Doxorubicin—bone cancer	6.48e-05	0.000993	CcSEcCtD
Rifaximin—Rash—Doxorubicin—bone cancer	6.42e-05	0.000985	CcSEcCtD
Rifaximin—Dermatitis—Doxorubicin—bone cancer	6.42e-05	0.000984	CcSEcCtD
Rifaximin—Headache—Doxorubicin—bone cancer	6.38e-05	0.000978	CcSEcCtD
Rifaximin—Nausea—Doxorubicin—bone cancer	6.05e-05	0.000928	CcSEcCtD
